Funding Received
$6.5 Million in 1 Round from 3 Investors
Most Recent Funding
$6.5 Million Series B on July 6, 2011
Headquarters:
Chilworth
Description:
Vantia Therapeutics is a pharmaceutical company developing small molecule drugs for unmet medical needs.
Categories:
Biotechnology
Website:
http://www.vantia.com

Detailed Description

Update

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia’s strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.

Current Team (1)

Update

Past Team (1)

Update

Funding Rounds (1) - $6.5M

Update

Board Members and Advisors (1)

Update

Investors (3)

Update

Offices/Locations (1)

Update
  • Office

    Southampton Science Park

    1 Venture Road, Southampton,

    Chilworth, SO16 7NP

    GBR